Table 1 Associations of cyclin F with clinicopathological features in the TMA cohorts.
Variable | n (%) | Cyclin F/TMA_1_ | p | Variable | n (%) | Cyclin F/TMA_2 | p | ||
|---|---|---|---|---|---|---|---|---|---|
Low n = 34 | High n = 74 | Low n = 94 | High n = 78 | ||||||
Age | Age | ||||||||
≤ 60 | 45 (41.67) | 13 (28.89) | 32 (71.11) | 0.678 | ≤ 60 | 105 (61.05) | 56 (53.33) | 49 (46.67) | 0.754 |
> 60 | 63 (58.33) | 21 (33.33) | 42 (66.67) | > 60 | 67 (38.95) | 38 (56.72) | 29 (43.28) | ||
Sex | Sex | ||||||||
Male | 75 (69.44) | 26 (34.67) | 49 (65.33) | 0.370 | Male | 115 (66.86) | 62 (53.91) | 53 (46.09) | 0.871 |
Female | 33 (30.56) | 8 (24.24) | 25 (75.76) | Female | 57 (33.14) | 32 (56.14) | 25 (43.86) | ||
Grade | Grade | ||||||||
G1 | 24 (22.22) | 13 (54.17) | 11 (45.83) | 0.018 | Gx | 8 (4.65) | – | – | 0.017 |
G2 | 71 (65.74) | 19 (26.76) | 52 (73.24) | G1 | 138 (80.23) | 80 (57.97) | 58 (42.03) | ||
G3–G4 | 13 (12.04) | 2 (15.38) | 11 (84.62) | G2–G3 | 26 (15.12) | 8 (30.77) | 18 (69.23) | ||
pT status | pT status | ||||||||
T1 | 34 (31.48) | 16 (47.06) | 18 (52.94) | 0.055 | T1 | 117 (68.02) | 70 (59.83) | 47 (40.17) | 0.051 |
T2 | 29 (26.85) | 8 (27.59) | 21 (72.41) | T2–T4 | 55 (31.98) | 24 (43.64) | 31 (56.36) | ||
T3–T4 | 45 (41.67) | 10 (22.22) | 35 (77.78) | – | – | – | – | ||
pN status | TNM stage | 0.034 | |||||||
N0 | 101 (93.52) | 33 (32.67) | 68 (67.33) | 0.429 | I | 118 (68.60) | 71 (60.17) | 47 (39.83) | |
N+ | 7 (6.48) | 1 (14.29) | 6 (85.71) | II–IV | 54 (31.40) | 23 (42.59) | 31 (57.41) | ||
